Table 2.

Demographics and clinical characteristics between the immunotherapy responder and non-responder groups

Characteristics	Responder	Non-responder	Total	P-value
No	8 (72.7)	3 (27.3)	11 (100.0)
Age	63.0 (54.5, 73.8)	62.0 (50.0, 62.0)	63.0 (54.0, 74.0)	0.840
Gender				0.491
Male, n (%)	7 (87.5)	2 (66.7)	9 (81.8)
Female, n (%)	1 (12.5)	1 (33.3)	2 (18.2)
Smoking history				0.179
Current or former, n (%)	7 (87.5)	2 (66.7)	9 (81.8)
Never, n (%)	1 (12.5)	1 (33.3)	2 (18.2)
Pack-years	35.0 (30.0, 40.0)	41.5 (33.0, 41.5)	35.0 (30.0, 45.0)	0.526
Neutrophil–lymphocyte ratio	2.63 (2.13, 4.36)	1.98 (1.86, 1.98)	2.27 (1.98, 3.76)	0.133
PD-L1 ≥ 10%	2 (25.0)	1 (33.3)
PD-L1 < 10%	6 (75.0)	2 (66.7)
Stage				0.361
I/II/III/IV, n	0/0/4/4	0/0/1/2	0/0/5/6
Pathologic diagnosis				0.661
Adenocarcinoma, n (%)	6 (75.0)	2 (66.7)	8 (72.7)
Squamous cell carcinoma, n (%)	2 (25.0)	1 (33.3)	3 (27.3)